A clinical trial update dated August 21, 2026 reports that a study of Lu-177-DOTATATE (Lutathera) is currently recruiting participants. The trial, registered as NCT03206060, is titled "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/Paraganglioma." It is listed as a Phase 2 study. Lu-177-DOTATATE is a radiolabeled somatostatin analog therapy being evaluated in this trial for patients with inoperable pheochromocytoma or paraganglioma. The trial's current status is recruiting, meaning it is actively enrolling participants as of the date of this update. No results or outcome data have been reported in connection with this update. The trial record does not include efficacy or safety findings at this stage. This brief reflects only the recruitment status and phase information provided in the trial listing. Somatostatin and its analogs remain classified as unapproved for this specific research application. Readers interested in the broader context of somatostatin as a compound, including its established uses and mechanisms, can consult the compound overview for additional background.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT03206060"]